...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >3D in vivo dose verification of entire hypo-fractionated IMRT treatments using an EPID and cone-beam CT.
【24h】

3D in vivo dose verification of entire hypo-fractionated IMRT treatments using an EPID and cone-beam CT.

机译:使用EPID和锥束CT对整个次分割IMRT治疗进行3D体内剂量验证。

获取原文
获取原文并翻译 | 示例
           

摘要

As radiotherapy becomes more complicated, dose and geometry verification become more necessary. The aim of this study was to use back-projected EPID-based 3D in vivo dosimetry and cone-beam CT (CBCT) to obtain a complete account of the entire treatment for a select patient group. Nine hypo-fractionated rectum IMRT patient plans were investigated. The absolute dose was reconstructed at multiple planes using patient contours and EPID images acquired for all fields during treatment. The meso-rectal fat (m-R) was re-delineated on daily CBCT scans, acquired prior to each fraction. The total accumulated dose was determined by mapping the m-R surface of each fraction to the planned m-R surface. Average planned and measured isocentre dose ratios were 0.98 (+/-0.01SD). 3D gamma analysis (3% maximum dose and 3mm) revealed mean gamma, gamma(mean)=0.35 (+/-0.03 SD), maximum 1% of gamma points, gamma(max1%)=1.02 (+/-0.14SD) and the percentage of points with gamma < or = 1, P(gamma < or = 1)=99% (range [96%, 100%]),averaged over all patients. CBCT m-R volumes varied by up to 20% of planned volumes, but remained in the high dose region. Over-dosage of up to 4.5% in one fraction was measured in the presence of gas pockets. By combining EPID dosimetry with CBCT geometry information, the total dose can be verified in 3D in vivo and compared with the planned dose distribution. This method can provide a safety net for advanced treatments involving dose escalation, as well as a full account of the delivered dose to specific volumes, allowing adaptation of the treatment from the original plan if necessary.
机译:随着放射疗法变得越来越复杂,剂量和几何形状验证变得更加必要。这项研究的目的是使用基于背投的基于EPID的3D体内剂量和锥形束CT(CBCT)来完整了解特定患者组的整个治疗方法。研究了九种低级直肠IMRT患者计划。使用患者轮廓和治疗期间针对所有视野获取的EPID图像,在多个平面上重建绝对剂量。在每天进行的CBCT扫描中重新划分中直肠脂肪(m-R),并在每个部分之前进行采集。通过将每个部分的m-R表面映射到计划的m-R表面来确定总累积剂量。计划和测得的平均等中心剂量比为0.98(+/- 0.01SD)。 3D伽玛分析(最大剂量3%,最大3mm)显示平均伽玛值,伽玛(平均值)= 0.35(+/- 0.03 SD),伽玛点最大1%,伽玛(最大1%)= 1.02(+/- 0.14SD) γ≤1的点的百分比,P(γ≤1)= 99%(范围[96%,100%]),在所有患者中平均。 CBCT m-R体积变化高达计划体积的20%,但仍处于高剂量区域。在存在气穴的情况下,测得的过量剂量高达一小部分的4.5%。通过将EPID剂量测定法与CBCT几何信息结合起来,可以在3D体内验证总剂量并将其与计划的剂量分布进行比较。这种方法可以为涉及剂量递增的高级治疗提供安全网,并且可以将所交付的剂量完全考虑到特定体积,并在必要时根据原始计划进行治疗调整。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号